Nipent (Pentostatin)

Pentostatin is a purine analog that inhibits the enzyme adenosine deaminase. This inhibition causes a buildup of deoxyadenosine nucleotides inside lymphocytes, disrupting DNA synthesis and leading to selective death of malignant B‑cells while sparing most other cell types.

The dosing regimen for Nipent is determined by the prescribing clinician based on the patient’s specific condition, disease stage, renal function, and other clinical factors. Healthcare professionals calculate the appropriate dose and schedule according to approved guidelines and individual patient needs.

Pentostatin is classified as contraindicated in pregnancy and breastfeeding unless the potential therapeutic benefit justifies the potential risk to the fetus or infant. Women of childbearing potential should use effective contraception, and lactating mothers should discuss alternatives with their healthcare provider.

To request Nipent, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

The primary alternative to Pentostatin in similar indications is fludarabine, another purine analog. While both agents suppress lymphocyte proliferation, Pentostatin has a distinct mechanism—adenosine deaminase inhibition—leading to different toxicity profiles. Choice between them depends on patient tolerance, prior therapy, and physician assessment.

Nipent should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should remain in its original packaging until use to maintain stability and sterility.

Nipent is administered by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are set by the prescriber and may be adjusted based on patient tolerance and clinical response.

The most serious risks include severe immunosuppression leading to opportunistic infections, acute respiratory distress syndrome, renal impairment, and cardiac arrhythmias. Patients should be monitored closely for signs of infection, respiratory difficulty, changes in kidney function, and cardiac abnormalities.

Nipent should not be used in patients with active uncontrolled infections, severe renal or hepatic impairment, known hypersensitivity to Pentostatin or any excipients, or in pregnant or breastfeeding women unless the benefits clearly outweigh the risks. Clinicians must evaluate each patient’s medical history before initiating therapy.